Download our whitepaper,

Heart Failure Clinical Trials:
Advanced Endpoint Strategies

What's Inside:

  • Defining acute pain endpoints and assessment tools
  • Rapid-onset analgesic evaluation methodologies
  • Patient selection criteria for acute pain studies
  • Post-surgical pain management trial designs
  • Safety and efficacy balance in acute pain treatment
  • Regulatory pathway insights for acute pain therapies

Access your complimentary whitepaper today:






    Hypercholesterolemia

    Hypercholesterolemia, marked by elevated cholesterol levels, is a significant contributor to cardiovascular disease, the leading global cause of death.

    Despite advancements in treatment, the complexity of the condition underscores the need for continued innovation in clinical trials to develop effective therapies and refine protocols.

    This whitepaper explores the critical aspects of hypercholesterolemia clinical trials, including diagnostic criteria, epidemiology, pivotal endpoints, and the challenges of endpoint determination. It also examines FDA-approved therapies, failed drug candidates, and common pitfalls in trial design, highlighting lessons from past failures. Safety concerns, a key consideration in lipid-lowering therapies, are addressed with strategies for risk mitigation.

    iNGENū’s team of researchers and clinicians is dedicated to advancing hypercholesterolemia research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by hypercholesterolemia.

    of people are undiagnosed, leaving them at higher cardiovascular risk

    85%

    of individuals with hypercholesterolemia have genetic or lifestyle-related causes

    99%

    adults in the U.S. has high total cholesterol levels

    1 in 5

    Our clinical team has over

    120

    years of combined clinical trial experience